Beyond elevating EPO plasma levels, Roxadustat could correct the degree of anemia by handling iron metabolism and particularly by decreasing hepcidin plasma levels, a response that is independent of the baseline CRP plasma levels and disease state of the CKD patient. The gene discussed is EPO; the disease is anemia (phenotype).